FDA Approves Adalimumab Biosimilar in High-Concentration Form FDA Approves Adalimumab Biosimilar in High-Concentration Form

The 100-mg/mL version of adalimumab-bwwd (Hadlima) is indicated for the same seven conditions as its 50-mg/mL counterpart.FDA Approvals
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Rheumatology News Alert Source Type: news